Literature DB >> 12029160

A model for the generation of multiple A to G transitions in the human respiratory syncytial virus genome: predicted RNA secondary structures as substrates for adenosine deaminases that act on RNA.

Isidoro Martínez1, José A Melero1.   

Abstract

Human respiratory syncytial virus (HRSV) escape mutants selected with antibodies specific for the attachment (G) protein contain diverse genetic alterations, including point mutations, premature stop codons, frame shift changes and A to G hypermutations. The latter changes have only been found in mutants selected with antibodies directed against the conserved central region of the G protein. This gene segment fulfils substrate requirements for adenosine deaminases that act on RNA (ADARs): i.e. it is an A+U rich region of 137 residues, and 98 or 106 of them--for A/Mon/3/88 or Long HRSV strains, respectively--are predicted to form intramolecular base pairs leading to a stable RNA secondary structure. In addition, when sequences of the G gene from natural isolates are compared in terms of pairwise substitutions, A to G+G to A changes are preferentially observed in regions where stable intramolecular dsRNA secondary structures are predicted to occur. In this study, a model is proposed in which, in addition to nucleotide misincorporations, reiterative A to G changes in HRSV are generated by ADAR activity operating in short segments (100-200 ribonucleotide residues) of the HRSV genome with high tendency for intramolecular base pairing.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12029160     DOI: 10.1099/0022-1317-83-6-1445

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  17 in total

Review 1.  Viral quasispecies evolution.

Authors:  Esteban Domingo; Julie Sheldon; Celia Perales
Journal:  Microbiol Mol Biol Rev       Date:  2012-06       Impact factor: 11.056

2.  Genetic and antigenic variability of human respiratory syncytial virus (groups a and b) isolated over seven consecutive seasons in Argentina (1995 to 2001).

Authors:  Monica C Galiano; Concepcion Palomo; Cristina M Videla; Juan Arbiza; José A Melero; Guadalupe Carballal
Journal:  J Clin Microbiol       Date:  2005-05       Impact factor: 5.948

Review 3.  Enhancement of replication of RNA viruses by ADAR1 via RNA editing and inhibition of RNA-activated protein kinase.

Authors:  Jean-François Gélinas; Guerline Clerzius; Eileen Shaw; Anne Gatignol
Journal:  J Virol       Date:  2011-04-13       Impact factor: 5.103

Review 4.  ADARs: viruses and innate immunity.

Authors:  Charles E Samuel
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

Review 5.  Adenosine deaminases acting on RNA (ADARs) are both antiviral and proviral.

Authors:  Charles E Samuel
Journal:  Virology       Date:  2011-01-05       Impact factor: 3.616

Review 6.  Animal pneumoviruses: molecular genetics and pathogenesis.

Authors:  Andrew J Easton; Joseph B Domachowske; Helene F Rosenberg
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

7.  The E3 ubiquitin ligase tripartite motif 33 is essential for cytosolic RNA-induced NLRP3 inflammasome activation.

Authors:  Leiyun Weng; Hiroki Mitoma; Coline Trichot; Coline Tricot; Musheng Bao; Ying Liu; Zhiqiang Zhang; Yong-Jun Liu
Journal:  J Immunol       Date:  2014-08-29       Impact factor: 5.422

8.  The DHX33 RNA helicase senses cytosolic RNA and activates the NLRP3 inflammasome.

Authors:  Hiroki Mitoma; Shino Hanabuchi; Taeil Kim; Musheng Bao; Zhiqiang Zhang; Naoshi Sugimoto; Yong-Jun Liu
Journal:  Immunity       Date:  2013-07-18       Impact factor: 31.745

9.  Extremely High Mutation Rate of HIV-1 In Vivo.

Authors:  José M Cuevas; Ron Geller; Raquel Garijo; José López-Aldeguer; Rafael Sanjuán
Journal:  PLoS Biol       Date:  2015-09-16       Impact factor: 8.029

10.  Comparative mutational analyses of influenza A viruses.

Authors:  Peter Pak-Hang Cheung; Igor B Rogozin; Ka-Tim Choy; Hoi Yee Ng; Joseph Sriyal Malik Peiris; Hui-Ling Yen
Journal:  RNA       Date:  2014-11-17       Impact factor: 4.942

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.